JTEKT India (standalone) PAT falls 4% YoY to ₹17.5 Cr as margins compress, revenue +31%
PAT -4.1% YoY · revenue +30.61% · margins compressing
₹834.74 Cr
+30.61% YoY
₹17.48 Cr
-4.1% YoY
2.09%
-0.8pp YoY
₹0.63
JTEKT India's standalone revenue rose 30.6% YoY and 16.3% QoQ to ₹834.7 Cr, but standalone PAT of ₹17.5 Cr came in 4.1% lower YoY (vs ₹18.2 Cr in Q2 FY26) even as it jumped 181% QoQ off an unusually weak June-quarter base of ₹6.2 Cr. EPS was ₹0.63 against ₹0.68 a year ago and ₹0.22 in Q1 FY27. There were no exceptional items in either period, so the YoY profit decline is a clean, unadjusted read on margins rather than a one-off distortion.
Q2 FY-2027 vs prior quarters
The margin bridge: NPM compressed to 2.09% from 2.84% YoY and OPM to 6.54% from 7.24%, even though both expanded sequentially from Q1's depressed 0.86%/5.32% — consistent with management's prior-quarter comment that near-term margin pressure from product mix and accounting issues would normalize. The YoY squeeze was driven by finance costs nearly tripling to ₹5.20 Cr (from ₹1.90 Cr) and employee costs rising ~20% to ₹80.93 Cr, as non-current borrowings climbed 45% since March 2026 (to ₹289.1 Cr) to fund ongoing capex — PP&E rose to ₹938.8 Cr from ₹808.1 Cr over the same period.
The stock went into the print at ₹123.13, up 8.3% over the past month of trading.
For context: revenue is at a 6-quarter high.
Management is optimistic about continued revenue growth, expecting to add approximately INR 800 crores in the next year through a combination of market growth and increased export business. They anticipate full capacity utilization for newly commissioned lines within the next 1 to 1.5 years, leading to improved ROCE. W
— This quarter: missed
No company-specific Q2 FY27 street preview was found; the only available read is Trendlyne's FY27 full-year consensus of roughly -14.4% profit growth, directionally in line with the margin pressure seen this quarter, so vsStreet is graded unknown at the quarter level rather than inferred. Against management's own prior guidance, the revenue-growth leg is tracking well — H1 FY27 revenue is already up ₹347.6 Cr YoY (₹1,552.7 Cr vs ₹1,205.1 Cr) against a stated full-year target of ~₹800 Cr incremental revenue — but the explicitly guided margin improvement from higher-value CVJ products and export mix has not yet shown up YoY, so guidance is graded missed on that dimension even as volume delivers. The filing carries no separate MD&A or press-release commentary beyond the board outcome letter, which otherwise covers a new CVJ capacity-expansion approval (22 Oct 2026), a ₹2.4 Cr captive solar power investment (26% stake in an SPV, approved alongside results) and the FY26 final dividend of ₹0.75/share paid during the quarter.
W1
OPM still trails year-ago levels (6.54% vs 7.24%) — watch Q3 FY27 OPM to confirm the CVJ/export mix shift is genuinely lifting margins, not just Q1-base normalization.
W2
Newly approved CVJ line capacity expansion (22 Oct 2026) — watch commissioning and utilization ramp, which management said would take 1–1.5 years to reach full capacity.
W3
H1 FY27 revenue is already up ₹347.6 Cr YoY against management's full-year target of ~₹800 Cr incremental revenue — watch H2 run-rate against that target.
Standalone only — company has no subsidiary/associate/JV as of 30 Sep 2026, so no consolidated statement exists. Figures converted from ₹ Lakh to ₹ Crore. No exceptional items in either the current or year-ago quarter, so the YoY PAT comparison is like-for-like (FY26's ₹5.98 Cr full-year exceptional VSS/labour-code charge sits outside both quarters compared here).